Inovio Pharmaceuticals, Inc. (NYSEMKT:INO) announced the appointment of E.J. Brandreth as Vice President of Quality. Inovio Pharmaceuticals Inc. (NYSEMKT:INO) shares after opening at $3.47 moved to $3.53 on last trade day and at the end of the day closed at $3.47. Company price to sales ratio in past twelve months was calculated as 61.59 and price to cash ratio as 15.81. Inovio Pharmaceuticals Inc. (NYSEMKT:INO) showed a positive weekly performance of 7.43%.
Research analysts at Credit Suisse lowered their price objective on shares of Exelixis (NASDAQ:EXEL) from $6.00 to $5.00 in a report released on Wednesday, StockRatingsNetwork.com reports. Credit Suisse’s target price suggests a potential upside of 29.53% from the company’s current price. Exelixis, Inc. (NASDAQ:EXEL) shares advanced 0.54% in last trading session and ended the day on $3.69. EXEL return on equity ratio is recorded as -150.50% and its return on assets is -42.00%. Exelixis, Inc. (NASDAQ:EXEL) yearly performance is -16.89%.
Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) announced that it will have two poster presentations at the 2014 American Association for Cancer Research (AACR) Annual Meeting. The conference will take place in San Diego, California, on April 5-9, 2014 at the San Diego Convention Center. Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) shares moved up 12.28% in last trading session and was closed at $1.28, while trading in range of $1.16 – $1.29. Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) year to date (YTD) performance is 150.98%.
Gilead Sciences Inc. (NASDAQ:GILD) announced after the close Wednesday that its Phase 3 clinical trial in Japan evaluating the once-daily sofosbuvir in combination with ribavirin, for the treatment of genotype 2 chronic hepatitis C virus infection, met its primary efficacy endpoint of superiority compared to a predefined historical control sustained virologic response rate. Gilead Sciences, Inc. (NASDAQ:GILD) weekly performance is 1.62%. On last trading day company shares ended up $73.96. Gilead Sciences, Inc. (NASDAQ:GILD) distance from 50-day simple moving average (SMA50) is -6.61%. Analysts mean target price for the company is $99.20.
Leave a Reply